Plymouth Meeting-based Inovio Pharmaceuticals is on the right track to launch its first product which would also be the first DNA medicine in the United States, writes John George for the Philadelphia Business Journal.

The biotechnology company has had a rough two-year stretch during which it parted ways with its founding CEO, implemented several layoff rounds, and stopped its work on a potential COVID-19 vaccine.

However now that it has shifted its full attention to a new lead drug candidate, the company believes it is on the right track.

“After many difficult months and quarters, I’m pleased to see the collective efforts of our dedicated and experienced team make a real difference,” said Inovio CEO Dr. Jacqueline Shea. “We are closer than ever to delivering on the promise of DNA medicines.”

DNA medicines deliver therapies directly into the body’s cells to produce an immune response that treats or prevents disease.

Inovio’s lead product candidate is INO-3107 which is currently in late-stage development as a treatment for respiratory papillomatosis.

According to Shea, the company has made “significant progress” on the new drug in the last two months.

Read more about Inovio Pharmaceuticals and DNA Medicine in the Philadelphia Business Journal.

_________________